NeoGenomics Inc. (NEO)
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript
Neo Energy Metals shares surge 33% as ex-Sibanye chief Froneman joins as chairman
Neo Energy Metals PLC (LSE:NEO) shares surged 33% to 11.02p after the uranium and gold developer announced a sweeping boardroom overhaul headlined by the appointment of Neal Froneman, the former chief executive of mining giant Sibanye-Stillwater, as independent non-executive chairman. Froneman, who led Sibanye-Stillwater from its formation in January 2013 until September 2025, oversaw its transformation from a 1.5 million-ounce South African gold producer into a globally diversified metals company and the world's largest primary producer of platinum group metals.
After Plunging 22.8% in 4 Weeks, Here's Why the Trend Might Reverse for NeoGenomics (NEO)
NeoGenomics (NEO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
NeoGenomics (NEO) Q4 Earnings and Revenues Surpass Estimates
NeoGenomics (NEO) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.04 per share. This compares to earnings of $0.04 per share a year ago.
NeoGenomics Announces Launch of New Cancer Assay PanTracer Pro
NEO launches PanTracer Pro, a pan-solid tumor assay built to streamline genomic testing and speed treatment decisions in advanced cancers.
NeoGenomics: Distribution Moat In Community Oncology
NeoGenomics is transitioning from a commodity diagnostic provider to a comprehensive precision oncology platform, leveraging deep relationships with community oncologists. NEO's clinical services revenue grew 18% YoY in Q3 2025, with high-value Next Generation Sequencing now nearly one-third of clinical revenue and outpacing market growth. The upcoming RaDaR ST launch in Q1 2026 positions NEO as a fast follower in the $20B MRD market, capitalizing on its established distribution and workflow integration.
NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NeoGenomics, Inc. (NEO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
NeoGenomics, Inc. (NEO) Q3 2025 Earnings Call Transcript
NeoGenomics, Inc. (NASDAQ:NEO ) Q3 2025 Earnings Call October 28, 2025 8:30 AM EDT Company Participants Priya Vedaraman Anthony Zook - CEO & Director Jeffrey Sherman - Chief Financial Officer Warren Stone - President & COO Conference Call Participants David Westenberg - Piper Sandler & Co., Research Division Andrew Brackmann - William Blair & Company L.L.C., Research Division Mason Carrico - Stephens Inc., Research Division Thomas Stevens - TD Cowen, Research Division Thomas VonDerVellen - Guggenheim Securities, LLC, Research Division Yuko Oku - Morgan Stanley, Research Division Puneet Souda - Leerink Partners LLC, Research Division Vidyun Bais - BTIG, LLC, Research Division Joseph Conway - Needham & Company, LLC, Research Division Presentation Operator Good morning, everyone, and welcome to the NeoGenomics Third Quarter 2025 Financial Results Call.
NeoGenomics (NEO) Surpasses Q3 Earnings and Revenue Estimates
NeoGenomics (NEO) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of $0.02 per share. This compares to earnings of $0.05 per share a year ago.
NeoGenomics (NEO) Moves 6.3% Higher: Will This Strength Last?
NeoGenomics (NEO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
NeOnc Technologies: From Survival Mode To Expansion Mode
NeOnc Technologies Holdings is a micro-cap biotech focused on innovative brain cancer treatments, NEO100 and NEO212, both in early clinical trials. NTHI's financials are challenging, with no revenue, rising R&D expenses, and a significant cash burn, but a $50M Quazar partnership is set to transform its outlook. The Quazar deal will provide crucial funding, pay off debts, and enable NTHI to accelerate clinical development and expansion in the MENA region.
